Migraine is one of the most prevalent neurological illnesses occurring in approximately 10 % of the US population, with a total prevalence of up to 29.6 % if probable migraine is also considered.
hours after an attack with sustained elevation through the sixth hour time point. The levels were assessed again after the end of the attack, with prostaglandin levels falling below those recorded 30 minutes after headache onset. Levels of nitrites, NKA and the intracellular messengers cyclic guanosine monophosphate (cGMP), calcitonin gene-related peptide (CGRP) peaked at the first hour then gradually decreased to levels lower than those at headache onset. These data suggest a relationship between the activation of the L-arginine/nitric oxide pathway, the release of vasoactive peptides from trigeminal endings, and a late rise in the synthesis of prostanoids which may be involved in maintaining the headache phase. 21 
Acute Migraine Treatment
For several years, treatment of acute migraine has been based on a stratified approach utilizing more-'specific' therapy targeted to migraine pathophysiology depending on the severity of headache. This approach has been validated as not only more effective for headache treatment but more cost effective as well. Treatment with analgesics such as acetaminophen or the use of over the counter non-steroidal anti-inflammatory drugs (NSAIDs) are recommended for patients with only mild headache. For patients with moderate to severe headaches, approved therapeutic options include selective serotonin receptor (5-HT 1 ) agonists (triptans), 22 Cambia ® (diclofenac potassium for oral solution) and ergot alkaloids. The latter are non-selective 5-HT 1 agonists that have a wider spectrum of receptor affinities outside of the 5-HT 1 system, including dopamine receptors.
Although triptans, ergot alkaloids and Cambia have been approved by the FDA as effective for migraine treatment, more than 25 % of patients with migraine are dissatisfied with their current treatment 23 and nearly 80 % would be willing to try an alternative. 24 Triptans are generally considered superior to ergot alkaloids from both an efficacy and side-effect perspective. 25 However, intolerance of side effects (blood vessel constriction, chest pain/pressure/tightness, esophageal spasm, dizziness, fatigue, nausea, light headedness, etc.) is also a major source of dissatisfaction with triptans, leading to the need for a viable alternative. 26 It is for this reason that certain NSAIDs, such as Cambia, have been re-examined as a potential treatment alternative for acute migraine.
Diclofenac has a long history of use in a variety of forms. 27 As a member of the NSAID class, it not only suppresses peripheral inflammation in migraine but also acts centrally to limit central sensitization. 28, 29 In • one or more fully reversible aura symptoms indicating brain dysfunction;
• at least one aura symptom develops gradually over more than four minutes or two more symptoms occur in succession;
• no single aura symptom lasts more than one hour; and/or
• headache follows aura with free interval of less than one hour Two or more of the following Other causes for headache excluded headache symptoms:
• unilateral location;
• pulsating quality;
• moderate to severe intensity; and/or
• aggravated by routine activity
At least one of the following associated symptoms:
• nausea or vomiting; and/or
• phonophobia and photophobia
Other causes for headache excluded 
Cambia ® in the Treatment of Acute Migraine
Cambia is a novel, patented formulation of diclofenac potassium that is the only prescription strength NSAID approved and indicated by the FDA for the acute treatment of migraine. It offers several advantages over conventional diclofenac tablets in that it is a 50 mg packet of powder that is buffered and used in solution to improve peak absorption of the medication. 32 Consequently, when compared with oral diclofenac pills, peak absorption for Cambia occurs within 15 minutes in contrast to pills or other forms of non-buffered diclofenac for which peak absorption occurs around 60 minutes. 33 Only injectable pharmacotherapies are faster. This feature of rapid peak absorption is critical in the treatment of migraine because it has been shown that early intervention may reduce central sensitization in rat models, 16 leading to supportive early treatment research paradigms in humans, aimed at improving the acute treatment of migraine. 34, 35 Furthermore, Cambia's buffered oral solution provides efficacy in such cases when the possibility of gastroparesis is of concern.
There have been two large pivotal multicenter trials of Cambia in the acute treatment of migraine-one in Europe 27 (see Figures 1 and 2 and who were pain-free after using Cambia remained pain-free at 24 hours as opposed to 15.3 % with diclofenac and 9.4 % with placebo. Cambia and diclofenac tablets were both superior to placebo for two hour reduction of nausea, photophobia, and phonophobia. 27 The US IMPACT trial was a randomized, double-blind, parallel-group, placebo-controlled study conducted in 23 US centers, involving 690 participants. Adult sufferers treated a moderate to severe attack with 50 mg Cambia (n=343) or placebo (n=347), similar to the European trial.
Cambia resulted in a two-hour pain-free response (25 versus 10 % for placebo, p<0.001). The differences between Cambia and placebo were apparent at 30 minutes post dose with continued significant difference throughout all measured time points. Interestingly, 19 % of those receiving Cambia versus 7.2 % from the placebo group remained pain-free at 24 hours (p<0.001), and Cambia was again superior to placebo with patients being free from nausea, photophobia, and phonophobia. 36 Side effects of Cambia in both studies were similar to placebo with overall incidence of all adverse events of about 6-7 % 27 with the greatest side-effect reported for Cambia being nausea of 4.6 % compared with placebo of 3.5 %. Patients at risk include older people, those taking diuretics or angiotensin-converting enzyme inhibitors, those with renal impairment, heart failure, or liver impairment.
Many of the patients one sees in the clinic overuse caffeinated medication leading to the phenomenon of caffeine withdrawal headache, causing them to develop headache as soon as the effects of each dose dissipates. 41, 42 One of the most common forms of the medications in question is caffeinated, powdered aspirin. It is of great benefit to be able to offer a powdered substitute that provides a sense of comfort and familiarity that patients may not have with pills. Half the battle of success is patient confidence in the medication they are using.
It has been noted that patients are often given tapers of medication to compensate for withdrawal headache or status migrainosus, a headache that persists for more than 72 hours. 6 A steroid taper with prednisone or dexamethasone is a common choice for such instances, [43] [44] [45] but many patients express intolerance to steroids, either from steroid-induced side effects (mania, insomnia, GI distress, etc.) or have conditions such as diabetes where steroids, could exacerbate the primary condition.
Using Cambia in such instances with a strategy of one dose twice daily for three days followed by a daily dose for three days has A small study comparing rizatriptan alone with combinations of rizatriptan, plus a COX-2 enzyme inhibitor (rofecoxib) or rizatriptan, plus a traditional NSAID (tolfenamic acid) showed decreased migraine recurrence rates in both treatment groups. 52 However, another study of patients with migraine-associated nausea found that the combination of therapy with triptan and NSAIDs appears to be less effective in relieving nausea than triptan monotherapy. 53 Looking at the evidence-based advantage of early intervention, 16, 34, 35 it makes sense to employ a rapidly absorbed anti-inflammatory medication such as Cambia with a triptan. From personal experience, such a strategy is beneficial for patients in whom Cambia alone or a triptan alone is insufficient to manage headaches.
Conclusion
In summary, migraine is a disabling disorder for which treatment is often unsatisfactory. Clinical trial data have demonstrated that Cambia significantly improves pain-free symptoms even in moderate to severe headache with rapid efficacy, sustained relief, and reduction of the associated features of migraine compared with tablet form and placebo. In a busy headache practice, it has been useful as a first-line treatment for migraine, treatment of status migrainosus, use in patients who cannot tolerate triptans, treatment for patients who prefer medication in solution, treatment for patients in withdrawal from other medications, and as an adjunctive treatment to triptans. Cambia is a versatile and efficacious tool for migraine management, is a welcome addition to the treatment armamentarium, and can help us improve our ability to achieve the goal of patient satisfaction. n
